The Foundation calls on the health plan to reverse its decision to remove CFTR modulators from marketplace and small employer plan formularies as required by patient protections guaranteed in the Affordable Care Act. The letter was also sent to insurance commissioners in Utah, Nevada, Colorado, and Idaho.
Site Search
Ad hoc patient advocacy coalition provided feedback to the U.S. Department of Health and Human Services on Massachusetts’ proposal to provide retroactive Medicaid coverage, continuous eligibility, and increased eligibility for marketplace subsidies.
The Cystic Fibrosis Foundation expressed support to the New Jersey General Assembly for A1255, Ensuring Transparency in Prior Authorization, which makes several important reforms to the prior authorization process.
The Cystic Fibrosis Foundation sent feedback to the Maryland Prescription Drug Affordability Board on their proposed Cost Review Study Process.
The CF Foundation provided feedback to Hawaii’s Medicaid director, commending Hawaii’s efforts to provide multi-year, continuous Medicaid coverage for children under six as well as two-year continuous eligibility for older children.
The CF Foundation expressed support to members of the Wisconsin State Legislature on LRB 1683/1, legislation that would provide a number of measures to protect patients’ access to medication, including requiring insurers to apply third-party assistance to out-of-pocket-maximums and other patient cost-sharing requirements.
CF Foundation joins 1,098 organizations strongly urging Congressional leadership to finish the FY24 appropriations process and adopt the bipartisan Senate funding framework as a starting point for final negotiations.
The Cystic Fibrosis Foundation joined the Partnership for Protecting Coverage in providing feedback to the Departments of Treasury, Labor, Health and Human Services, and the Office of Personnel Management on new provisions outlined in the No Surprises Act.
In the statement, the Partnership for Protecting Coverage applauded efforts by the Department of Labor to reverse previous decisions to eliminate or substantially alter standards and regulatory structures of association health plans, including requiring these plans to cover essential health benefits.
In the letter to the Federal Trade Commission, the Cystic Fibrosis Foundation asks the commissioner to take appropriate enforcement action against alternative funding programs, emphasizing the harmful consequences of these programs on people with CF.